Rapact
Rapact (Sirolimus 5/10 mg) — Sun Pharma mTOR inhibitor for solid-organ transplant maintenance, lymphangioleiomyomatosis, tuberous sclerosis-associated tumours.
✓ Medisinsk vurdert av Morgan Ellis — Farmasøytisk forsker · 8 års erfaring · Sist gjennomgått: mai 2026
Kort svar
Rapact — Sirolimus (Rapamycin) 5/10 mg (Sun Pharma). mTOR inhibitor for solid-organ transplant maintenance immunosuppression, lymphangioleiomyomatosis (LAM), tuberous sclerosis-associated angiomyolipomas, certain cancers. Therapeutic drug monitoring (target trough 5-15 ng/mL).
Hva du får med MedsBase:
- WHO-GMP-sertifisert produsent
- Diskré emballasje i vanlig konvolutt
- Verdensomspennende levering
- Vurdert av over 1 400 kunder (les anmeldelser)
📦 Reshipment Assurance: hvis din ordre ikke har kommet frem 20 virkedager etter forsendelse, sender vi den på nytt uten ekstra kostnad. Les policyen.
Hvorfor bestille fra MedsBase
Rapact ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Immunosuppressants need ongoing specialist supervision (transplant, rheumatology, or haematology). Drug levels (cyclosporine, sirolimus, tacrolimus), FBC, LFTs, renal function, lipids, glucose, BP — all need regular monitoring. Infection surveillance is mandatory. Vaccination status must be optimised before starting; live vaccines contraindicated during therapy.
Long-term immunosuppression increases risks: opportunistic infections (PCP, CMV, EBV-driven PTLD), bacterial/fungal infection, reactivation of latent TB or HBV/HCV. Increased risk of skin cancer (especially squamous cell), lymphoproliferative disease, and other malignancies. Annual skin checks, regular cancer surveillance per guidelines.
Vanlige spørsmål
When is this used?
mTOR inhibitor for solid-organ transplant maintenance immunosuppression, lymphangioleiomyomatosis (LAM), tuberous sclerosis-associated angiomyolipomas, certain cancers. Therapeutic drug monitoring (target trough 5-15 ng/mL). Always specialist-supervised — transplant, rheumatology, haematology, or oncology context.
Why is monitoring needed?
Therapeutic drug monitoring (cyclosporine, sirolimus, tacrolimus): trough levels target organ-protection without toxicity. Renal function: most are nephrotoxic. Lipids/glucose: metabolic effects. FBC: marrow suppression.
Legemiddelinteraksjoner?
Critical class — strong CYP3A4 substrates (calcineurin inhibitors, mTOR inhibitors). Many interactions: antifungals raise levels (often dramatically — even 5-10×), rifampicin drops levels (rejection risk), grapefruit raises levels. Any new medication should be checked first.
Vaccines?
Inactivated vaccines fine; live vaccines contraindicated during therapy. Optimise vaccinations BEFORE starting — pneumococcal, annual influenza, hepatitis B, varicella, MMR, HPV as appropriate.
Graviditet?
Mycophenolate is teratogenic — strict contraception. Cyclosporine, tacrolimus, azathioprine are used in pregnancy with specialist supervision. mTOR inhibitors generally avoided. Always discuss family planning with specialist.
Cancer screening?
Skin checks every 6-12 months (lifelong skin cancer risk). Cervical cytology more frequent. Lymph nodes — monitor for lymphoproliferative disease.
Infections?
Cotrimoxazole prophylaxis for PCP first 6-12 months post-transplant. CMV monitoring. TB screening before starting. Ongoing infection vigilance — fever needs prompt assessment.
Sun protection?
Daily broad-spectrum SPF 50+ from the day of transplant onwards. Annual dermatology review. Skin cancer is the most common post-transplant malignancy.
Hva om jeg glemmer en dose?
Take when you remember if same day; if >12 hours late, skip and resume next dose. Do not double up. Consistent levels matter — discuss adherence with your transplant team.
Stopping?
Never stop without specialist guidance — risks acute rejection (transplant) or disease flare (autoimmune). Tapers happen over months, not days, and only when clinically appropriate.
Other Immunosuppressant & Cancer Medications
- Mycept — mycophenolate mofetil 250 mg — alternative MMF brand
- Mycofit — mycophenolate mofetil 500 mg
- Cyclophil ME — cyclosporine ME 25/50/100 mg
- Renodapt S — mycophenolate sodium 360 mg — enteric-coated
- Rapact — sirolimus 5/10 mg — mTOR inhibitor
More options in Anti Cancer Medication
Rangert etter nylig bestillingsvolum på MedsBase — hva andre kunder i denne kategorien velger.
| Styrke | 5 mg, 10 mg |
|---|---|
| Antall | 28 tablett/er, 56 tablett/er, 84 tablett/er |
| Farmasøytisk form | Tablet/t |
| Produsent | Natco Pharma |
| Behandling | Breast cancer, Pancreatic cancer, Lung cancer |
| Generisk merke | Sirolimus |
Rapact
Spørsmål og svar
Rapact
Relaterte produkter
Anmeldelser
Det er ingen anmeldelser ennå